long at 10.60 and have already lost 20 cents
14:44 EDT - MiMedx's(MDXG) announced on New Year's Eve it received an HHS subpoena related to sales and marketing, and shares have spent all of 2015 in the red. But the stock is much closer to break-even today as the wound-care company says the Justice Department for now isn't getting involved in a lawsuit which prompted the subpoena. But that doesn't mean all is clear. MDXG bear Northland Capital notes its concerns haven't been based on the legal picture, but rather " concerns about the sustainability of Mimedx's(MDXG) growth trajectory," regulatory interpretations "and a changing reimbursement landscape." That as in general, the investment bank repeats prior commentary that "on a macro level, there appear to be questionable sales practices in the field." MDXG rises 8.5% to $11.10, cutting the year's drop to 3.7%.
At least the releases now confess "MDXG bear Northland Capital"
Also my SUGGESTION to buy shares was just that, suggestive.
Are you familiar with what a call buyer has the "right" to do? I suggest you pick up "options for dummies" since your simply "at a loss"
Busy washing your daddys car I'm betting.
First the company can "buy on close"
Second it was the 10k, my oversight
Third, since your too lazy to read the K and insist on avoiding to answer, let me go ahead and "spoon feed" you with a snippet and the magic three words at the end.
"We expect our research and development expenses to continue to be substantial in the future, as we continue our clinical trial activity for our existing Biosurgery products if and as they advance through the development cycle, and if and as we invest in additional product opportunities and research programs. Clinical trials and preclinical studies are time-consuming and expensive. Our expenditures on current and future preclinical and clinical development programs are subject to many uncertainties. We test our products in several preclinical studies, and we then conduct clinical trials for those candidates that we determine to be the most promising. As we obtain results from clinical trials, we may elect to discontinue or delay trials for some product candidates in order to focus our resources on more promising product candidates. Completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, size of trial and intended use of a product candidate."
how_bout, your just such a cleaver, quick witted cheeky sort of fellow aren't ya? You must be so proud.
bet you didn't notice the OSIR 10Q after the market close today did ya? Assuming you did -
Anything that strikes you about the report? Notice what was not discussed or mentioned?
Lets see how bright you are smart guy
If I were management I'd have an end of day plan that uses the buyback to bump us above 10 so the shorts don't get the ability to gather shares using the options
Just my 10 cents
it's always been expected one needs to "hold your nose" when it comes to the PPS movements in MDXG
technically a new range is being established and we have options expiration today
next week I suspect management may "flip some pins" IMHO
Silver your arguing with the dumbest kid in the classroom. Don't waste your time
Shorts I have only 2 words to summarize your situation ... MARGIN CALL
As a side note, ADK broke a big moving average today. Starting a long position.
The buzz seems real IMHO.
Thanks to whomever brought this one to light.
The commonality of the past 6 recent press releases is the word "deadline".
History shows us a "deadline" is called a deadline for a reason, the lawyers are running out of time.
The last time this playbook was used, around the untitled letter, the PPS went from 5 to 11.
Actions speak louder than words.
Long and strong MDXG
Last week Fidelity showed over 1 million shares available to short (HTB) at an interest rate of 1.25%
As of today there are no shares available. They have to call other brokers to get shares .. assuming they can get them.
This is a big shift and may suggest there is nothing that can be shorted.
MACD and RSI beginning a rise that started a day and 1/2 ago. Possible week closing short cover however this 8.50 are is key. Grind higher into the earnings report IMO
oh candy #$%$ - such a moron
had you read the filing he's about to acquire close to 3 million shares
that's 3 million more shares that will never be sold and you can't use to short
It's amazing how many shares the CEO owns. What it discloses in my mind is what we've known all along. Shares are positioned for estate planning and gifting purposes. He's NEVER sold a share since day one.
Put that in your pipe cez/candy and smoke it.